The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis.
Journal
Canadian journal of gastroenterology & hepatology
ISSN: 2291-2797
Titre abrégé: Can J Gastroenterol Hepatol
Pays: Egypt
ID NLM: 101623613
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
04
2021
revised:
27
05
2021
accepted:
09
06
2021
entrez:
9
7
2021
pubmed:
10
7
2021
medline:
19
8
2021
Statut:
epublish
Résumé
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease with wide ranges of reported incidence and prevalence. To map the incidence and prevalence of PBC in European countries from 2000 through 2020. Following PRISMA recommendations, we searched the Medline and Scopus databases for studies with information on either the incidence or prevalence of PBC. After data extraction, we used a random-effects model to estimate both the pooled annual incidence rate and pooled point-prevalence rate and performed subgroup analyses to identify components contributing to between-study heterogeneity. We performed a qualitative and quantitative analysis of 18 studies. The pooled point-prevalence rate was 22.27 cases per 100,000 inhabitants (95% CI: 17.98-27.01), and the pooled annual incidence rate was 1.87 new cases per 100,000 inhabitants (95% CI: 1.46-2.34). In the subgroup analyses, we proved that a small part of the between-study heterogeneity is significantly associated with a history of being part of the Eastern Bloc.
Sections du résumé
Background
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease with wide ranges of reported incidence and prevalence.
Aim
To map the incidence and prevalence of PBC in European countries from 2000 through 2020.
Methods
Following PRISMA recommendations, we searched the Medline and Scopus databases for studies with information on either the incidence or prevalence of PBC. After data extraction, we used a random-effects model to estimate both the pooled annual incidence rate and pooled point-prevalence rate and performed subgroup analyses to identify components contributing to between-study heterogeneity.
Results
We performed a qualitative and quantitative analysis of 18 studies. The pooled point-prevalence rate was 22.27 cases per 100,000 inhabitants (95% CI: 17.98-27.01), and the pooled annual incidence rate was 1.87 new cases per 100,000 inhabitants (95% CI: 1.46-2.34). In the subgroup analyses, we proved that a small part of the between-study heterogeneity is significantly associated with a history of being part of the Eastern Bloc.
Identifiants
pubmed: 34239845
doi: 10.1155/2021/9151525
pmc: PMC8238597
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9151525Informations de copyright
Copyright © 2021 Jakub Gazda et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Clin Rev Allergy Immunol. 2018 Apr;54(2):295-306
pubmed: 29181702
N Engl J Med. 2018 Jun 07;378(23):2171-2181
pubmed: 29874528
Dig Liver Dis. 2019 May;51(5):724-729
pubmed: 30584000
Trends Immunol. 2009 Aug;30(8):415-20
pubmed: 19643668
Semin Liver Dis. 2020 Feb;40(1):34-48
pubmed: 31537031
Sci Rep. 2016 May 19;6:25906
pubmed: 27192935
Eur J Gastroenterol Hepatol. 2007 Oct;19(10):859-64
pubmed: 17873609
N Engl J Med. 2016 Aug 18;375(7):631-43
pubmed: 27532829
Hepatol Int. 2019 Nov;13(6):788-799
pubmed: 31552558
Int J Public Health. 2020 Jun;65(5):683-691
pubmed: 32500239
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
Dig Dis. 2015;33 Suppl 2:2-12
pubmed: 26641102
Croat Med J. 2019 Dec 31;60(6):494-502
pubmed: 31894914
Scand J Gastroenterol. 2007 Nov;42(11):1347-53
pubmed: 17918011
Sci Rep. 2019 Aug 8;9(1):11525
pubmed: 31395896
Hepatology. 2006 Mar;43(3):525-31
pubmed: 16496326
Am J Epidemiol. 2014 Feb 15;179(4):492-8
pubmed: 24401563
Gut. 2005 Apr;54(4):528-32
pubmed: 15753539
Eur J Intern Med. 2017 Jul;42:81-88
pubmed: 28535947
Dis Markers. 2010;29(6):329-36
pubmed: 21297252
Dis Markers. 2010;29(6):337-44
pubmed: 21297253
Eur J Gastroenterol Hepatol. 2012 Jul;24(7):824-30
pubmed: 22562114
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1342-1350.e1
pubmed: 29277621
Z Gastroenterol. 2020 May;58(5):431-438
pubmed: 32392605
J Gastroenterol Hepatol. 2021 Jun;36(6):1423-1434
pubmed: 33141955
Liver Int. 2014 Jul;34(6):e31-8
pubmed: 24387641
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Hepatol. 2010 Jul;53(1):162-9
pubmed: 20471130
Rev Esp Enferm Dig. 2018 Oct;110(10):641-649
pubmed: 30032637
Liver Int. 2014 Aug;34(7):e200-7
pubmed: 24502439
J Autoimmun. 2007 Aug;29(1):1-9
pubmed: 17582741